Search PubMed⌕ Search

Biomedical subjects

B Serrou

Publications and source records attributed to B Serrou.

At least 163 records · Page 9Linked to original sources
PubMedDate not supplied

Effects of low doses of irradiation on the T-cell-mediated cytotoxic response.

Statistically significant inhibition of the T-cell-mediated cytotoxic response was observed when mouse splenocytes were irradiated in vitro with 0.15 Gy prior to ConA and allogeneic stimulation. Restimulation in mixed lymphocyte culture demonstrated the same difference between irradiated and non-irradiated cultures as for the first stimulation. Adherent cell depletion of responder cells did not modify the inhibitory effect of 0.15 Gy on the cytotoxic response. The study of Lyt-6 markers on activation showed a decrease in the total number of activated cells (but not of the percentage) in cultures processed with irradiated cells. The data suggest that a T cell, involved in the generation of cytotoxic lymphocytes and present in the Lyt-2-depleted population, is the target of low-dose irradiation.

Animals↗
PubMedDate not supplied

Monolayer cell cultures as target cells for the study of lymphocyte cytotoxicity in cancer patients.

Lymphocytotoxicity using S3-Hela target cells has been studied in 20 cancer patients treated with ionizing radiation (head and neck, lung and breast cancers). Monolayer cultures of Hela cells were marked with radioactive 51 Chromium and cultured with non stimulated or phytohemagglutinin (PHA) stimulated lymphocytes. This study shows a spontaneous decrease of lymphocytotoxicity in cancer patients as compared with normal subjects and an immunodepressive effect of radiotherapy. We observe a significant decrease of lymphocytotoxicity for either stimulated or non-stimulated lymphocytes at the end of radiation treatment. Moreover one month after completion of radiotherapy a possible repair of a lymphocytoxicity seems to be related with a short-term (6 months) good prognosis.

Breast Neoplasms↗
PubMedDate not supplied

[Influence of treatment with ionizing radiations on the immune response of cancer patients].

We report the results of immunological surveillance of 60 patients with advanced ENT, mammary and bronchopulmonary cancers or Hodgkin's disease, treated only by physical agents. These patients were explored by blastic stimulation testing before, during and after radiation therapy. The results confirm an immunodepressive effect of radiotherapy which increase as the irradiated areas increase, thus showing the importance of immunological surveillance of the cancer patients especially after irradiation. In effect the correlation existing between the importance of immunological repair after irradiation and a good short-term prognosis lead us to plan new radio-immunotherapeutic associations in the treatment of advanced cancers or cancers with a poor prognosis.

Dose-Response Relationship, Radiation↗
PubMedDate not supplied

The effect of local irradiation on the immune response in mice. II.--Alterations due to low dose scattering.

The effect of localized irradiation given as single dose on the immune response of tumour-bearing mice was evaluated using the CRT. The tumour system (MBL2 on C57BL/6 females) was regularly lethal, although presence of CTL was demonstrated 15 days after transplantation (50,000 cells in the left hind limb). This T-dependent, antigen-specific cytotoxic activity observed on day 15 in the non-irradiated tumour-bearing group was abolished in the irradiated group (but not in the sham-irradiated group) and their CTL were incapable to mount a secondary response in MLTC-CML. The scattering of the 1,600 rad-single dose was sufficient to provoke this inhibition.

Animals↗
PubMedDate not supplied

Unanticipated effect of BCG in mice treated by radiotherapy.

Female C57 Bl/6 mice (6-8 weeks old) bearing the Lewis or the MBL-2 tumor received a localized irradiation (1,600 Rads; Cobalt 60) three days after the tumor implantation. We compared the association of irradiation and Immuno-BCG-F (1 mg/mice i.v.) with three control groups (no treatment, irradiation alone, Immuno-BCG-F alone). The timing and number of BCG injections varied in the different sub-groups. Results were improved in the Lewis tumor system when BCG was injected just after the end of the irradiation. Efficiency improved with the number of injections (P less than 0.05). In the MBL-2 system, depending on the timing of BCG injections we observed significant survival prolongation (irradiation + BCG) as compared to control groups. It has to be noted that the use of BCG alone enhanced tumor growth in two models.

Animals↗